Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Contemporary approaches to the management of R/R DLBCL

Tycel Phillips • 5 Jun 2022
ASCO 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Axicabtagene ciloleucel Bendamustine Loncastuximab tesirine Polatuzumab vedotin Rituximab Selinexor

Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, reflects on novel approaches in the management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), highlighting the approval of axicabtagene ciloleucel (axi-cel), as well as targeted approaches such as polatuzumab vedotin, an antibody-drug conjugate, in combination with bendamustine and rituximab. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Tycel Phillips

0:51
An update from ASH 2023: advancements in NHL treatment
Tycel Phillips • 10 Dec 2023
1:54
A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma
Tycel Phillips • 10 Dec 2023
1:55
Optimal sequencing of CAR-T and bispecifics in NHL
Tycel Phillips • 10 Dec 2023
1:17
GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL
Tycel Phillips • 10 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals